Literature DB >> 12404685

Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study.

Gad Lubin1, Abraham Weizman, Mordechai Shmushkevitz, Avi Valevski.   

Abstract

Eight patients (6 men and 2 women) with chronic post-traumatic stress disorder (PTSD) were treated with naltrexone 100-200 mg/day. Seven patients completed 2 weeks of treatment. A subtle and clinically insignificant improvement was noted in intrusive and hyperarousal symptoms (p < 0.05 for both), but not in avoidance symptoms. All patients demonstrated side effects which limited the targeted dose. It is suggested that the subtle positive effect of naltrexone and the hypersensitivity of these patients to its side effects do not encourage the use of naltrexone in the treatment of PTSD patients. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404685     DOI: 10.1002/hup.395

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  8 in total

Review 1.  Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review.

Authors:  William Berger; Mauro V Mendlowicz; Carla Marques-Portella; Gustavo Kinrys; Leonardo F Fontenelle; Charles R Marmar; Ivan Figueira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-12-24       Impact factor: 5.067

Review 2.  The missing p in psychiatric training: why it is important to teach pain to psychiatrists.

Authors:  Igor Elman; Jon-Kar Zubieta; David Borsook
Journal:  Arch Gen Psychiatry       Date:  2011-01

3.  [Low dose naltrexone in the treatment of dissociative symptoms].

Authors:  W Pape; W Wöller
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

Review 4.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 5.  Targeting memory processes with drugs to prevent or cure PTSD.

Authors:  Christopher K Cain; George D Maynard; John H Kehne
Journal:  Expert Opin Investig Drugs       Date:  2012-07-27       Impact factor: 6.206

Review 6.  Pharmacotherapy for anxiety and comorbid alcohol use disorders.

Authors:  Jonathan C Ipser; Don Wilson; Taiwo O Akindipe; Carli Sager; Dan J Stein
Journal:  Cochrane Database Syst Rev       Date:  2015-01-20

Review 7.  Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems.

Authors:  Terril L Verplaetse; Sherry A McKee; Ismene L Petrakis
Journal:  Alcohol Res       Date:  2018

8.  Reward and aversion processing in patients with post-traumatic stress disorder: functional neuroimaging with visual and thermal stimuli.

Authors:  Igor Elman; Jaymin Upadhyay; Daniel D Langleben; Mark Albanese; Lino Becerra; David Borsook
Journal:  Transl Psychiatry       Date:  2018-11-02       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.